December 2016
-
According to news reports, the US Federal Bureau of Investigation (FBI) has raided the San Diego, California headquarters of vaccine developer NexBio and removed papers. FBI agent Darrell Foxworth is quoted as saying that the… Read more . . .
-
Ten slots available for posters, with the top three posters chosen for a Posters on Podium session. Abstracts should be submitted by August 17, 2011 to Sai Prasanth Chamarthy or Jason Ehrick, co-chairs of the… Read more . . .
-
Two days after announcing that it had licensed VR315 in the US to an undisclosed pharmaceutical company, Vectura announced that Sandoz has licensed the product in the rest of the world. Sandoz already has an… Read more . . .
-
Finnish pharmaceutical company Orion Corporation will co-market combination products delivered by its Easyhaler dry powder inhaler with Nycomed. The agreement covers major European countries, the Middle East, and North Africa. Orion will manufacture the products… Read more . . .
-
University of Michigan spin-off NanoBio has licensed a novel respiratory syncytial virus (RSV) from the US National Institutes of Health (NIH). NIH developed the antigen using proprietary technology. No approved vaccine for RSV currently exists;… Read more . . .
-
Vectura is not saying which international pharmaceutical company’s US division has entered into a “collaboration, development, and license agreement” for the VR315 dry powder inhaler. VR315 is a fixed dose combination therapy for asthma and… Read more . . .
-
The UK Medicines and Healthcare products Regulatory Agency (MHRA) is warning consumers against using a “fake tan nasal spray” marketed as Ubertan. According to the agency, the product comes in two versions, one of which… Read more . . .
-
The US FDA has notified Insmed that it has placed a clinical hold on Insmed’s trials of Arikace liposomal amikacin for inhalation. The ongoing Phase 3 program for the use of Arikace in cystic fibrosis… Read more . . .
-
A goal date of March 26, 2012 has been set for the NDA submitted to the FDA for MAP Pharmaceuticals’ Levadex inhaled dihydroergotamine (DHE) for the treatment of migraine in adults. The acceptance triggered a… Read more . . .
-
Minneapolis, MN area. This company is looking for someone with experience in any type of drug/device combinations, including OINDPs; it is dedicated to the development and commercialization of the safest, most efficacious drug coated balloon… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland